Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1735-1742

  Yoon, Ju Yoon ^a,b   Lafarge, Sandrine ^b   Dawe, Dave ^b   Lakhi, Sunjay ^b   Kumar, Rajat ^b   Morales, Carmen ^b   Marshall, Aaron ^b   Gibson, Spencer B ^a,b   Johnston, James B ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CANCERCARE MANITOBA   (Canada)

Author keywords

2 microglobulin; Chronic lymphocytic leukemia; IL 6; IL 8; TNF

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; ELDERLY CARE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROMA CELL; TUMOR MICROENVIRONMENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN-6; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; TELOMERE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84864995278     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.666662     Document Type: Article

References (42)

1. Cawthon RM. Telomere lengThmeasurement by a novel monochrome multiplex quantitative PCR method. Nucleic AcidsResearch 2009;37:e21.
2. S eftel MD, Demers AA, Banerji V, et al. High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: population-based Canadian cohort population-based Canadian cohort. Leuk Res 2009;33:1463-1468.
3. Gentile M, Cutrona G, Neri A, et a l F. Predictive value of {beta}2- microglobulin ({beta}2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009;94:887-888.
4. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
5. R assenti LZ, Jain S, Keating MJ, et a l. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-1930.
6. H allek M, Fischer K, Fingerle-Rowson G, et a l. Addition of rituximab to fl udarabine and cyclophosphamide in patients wiThchronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
7. Letestu R, L é vy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: The strengThof routine parameters. Blood 2010;116:4588-4590.
8. Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is better predictor of treatment-free survival in patients wiThchronic lymphocytic leukaemia if adjusted according to glomerular fi ltration rate. Br J Haematol 2009;145:801-805.
9. Molica S, Levato D, Cascavilla N, et al. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and ǎ 2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999;62:117-122.
10. Fayad L, Keating MJ, Reuben JM, et a l. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation wiThphenotypic characteristics and outcome. Blood 2001;97:256-263.
11. Lai R, O'Brien S, Maushouri T, et al. Prognostic value of plasma interleukin-6 levels in patients wiThchronic lymphocytic leukemia. Cancer 2002;95:1071-1075.
12. W ierda WG, Johnson MM, Do K-A, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003;120:452-456.
13. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical signifi cance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100:1215-1219.
14. Francia di Celle P, Mariani S, Riera L, et al. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 1996;87: 4382-4389.
15. Jewell AP, Lydyard PM, Worman CP, et al. GrowThfactors can protect B-chronic lymphocytic leukaemia cells against programmed cell deaThwithout stimulating proliferation. Leuk Lymphoma 1995;18:159-162.
16. Wierda WG, O'Brien S, Wang X, et a l. Prognostic nomogram and index for overall survival in previously untreated patients wiThchronic lymphocytic leukemia. Blood 2007;109:4679-4685.
17. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated wiThimportant clinical end points in patients wiThchronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009;27:1637-1643.
18. B airey O, Ruchlemer R, Rahimi-Levene N, et a l. Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study. Ann Hematol 2011;90:1123-1129.
19. S hanafelt TD, Rabe KG, Kay NE, et a l. Age at diagnosis and the utility of prognostic testing in patients wiThchronic lymphocytic leukemia. Cancer 2010;116:4777-4787.
20. H arris TB, Ferrucci L, Tracy RP, et a l. Associations of elevated interleukin-6 and C-reactive protein levels wiThmortality in the elderly. Am J Med 1999;106:506-512.
21. B ruunsgaard H, Ladelund S, Pedersen AN, et al. Predicting deaThfrom tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 2003;132:24-31.
22. F errucci L, Corsi A, Lauretani F, et a l. The origins of age-related proinfl ammatory state. Blood 2005;105:2294-2299.
23. d i Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: Evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 1994;84:220-228.
24. B iondi A, Rossi V, Bassan R, et al. Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood 1989;73:1279-1284.
25. F ais F, Ghiotto F, Hashimoto S, et a l. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.
26. J elinek DF, Tschumper RC, Stolovitzky GA, et al. Identifi cation of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003;1:346-361.
27. J ohnston JB, Kabore AF, Strutinsky J, et a l. Role of the TRAIL//APO2-L deaThreceptors in chlorambucil- and fl udarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356-8369.
28. K urtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL B cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441-4450.
29. S ahyoun NR, Lentzner H, Hoyert D, et a l. Trends in causes of deaThamong the elderly. Hyattsville, MD: National Center for HealThStatistics; 2001.
30. H amblin AD, Hamblin TJ. The immunodefi ciency of chronic lymphocytic leukaemia. Br Med Bull 2008;87:49-62.
31. W iernik P. Second neoplasms in patients wiThchronic lymphocytic leukemia. Curr Treat Options Oncol 2004;5:215-223.
32. S chulz A, Toedt G, Zenz T, et a l. Infl ammatory cytokines and signaling pathways are associated wiThsurvival of primary chronic lymphocytic leukemia cells in vitro: A dominant role of CCL2. Haematologica 2011;96:408-416.
33. P lander M, Seegers S, Ugocsai P, et a l. Diff erent proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009;23:2118-2128.
34. B urger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood 2009;114:3367-3375.
35. V ilpo J, Vilpo L, Hurme M, et al. Induction of beta-2-microglobulin release in vitro by chronic lymphocytic leukaemia cells: Relation to total protein synthesis. Leuk Res 1999;23:913-920.
36. Jones RA, Drexler HG, Gignac SM, et al. In vitro beta 2-microglobulin (beta 2m) secretion by normal and leukaemic B-cells: Eff ects of recombinant cytokines and evidence for a diff erential response to the combined stimulus of phorbol ester and calcium ionophore. Br J Cancer 1990;61:675-680.
37. Wozniak S, Gee L, Wachtel M, et al. Adipose tissue: The new endocrine organ? A review article. Dig Dis Sci 2009;54:1847-1856.
38. Davalos A, Coppe J-P, Campisi J, et a l. Senescent cells as a source of infl ammatory factors for tumor progression. Cancer Metastasis Rev 2010;29:273-283.
39. Campisi J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 2005;120:513-522.
40. M oreno A, Villar ML, Cá mara C, et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001;97:242-249.
41. S chuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009;102:215-222.
42. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-6741.